AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Avalo Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$11.59+0.32 (+2.84%)

Close on Oct 19, 2026

Market cap: $505.35M
P/E (TTM): –
Dividend yield: –

Avalo Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31
Revenue	0.06	0.44	1.92	18	5.40	6.70	6.75	7.03	28	1.15	0	–	–
Cost of Revenue	–	–	1.28	3.43	1.49	0.30	-0.57	3.26	0.64	0	0	–	–
Gross Profit	–	–	0.64	15	3.91	6.40	7.32	3.77	27	1.15	0	–	–
Research & Development	50	24	14	31	60	32	12	5.79	4.37	10	6.59	12	8.91
Selling, General & Admin	–	–	10	21	27	20	12	11	8.51	7.08	4.42	–	–
Selling & Marketing	–	–	–	–	2.83	2.34	1.48	0.55	0.57	0	0	–	–
General & Administrative	23	17	10	21	25	17	10	11	7.94	7.08	4.42	4.88	4.02
Operating Expenses	–	–	–	–	–	–	–	58	14	17	11	–	–
Total Costs & Expenses	73	69	29	55	88	80	23	42	–	–	–	–	–
Operating Income	-73	-69	-27	-37	-82	-73	-16	-35	14	-16	-11	-17	-13
Other Non-Operating Income	-5.17	33	-4.18	-4.19	-2.41	5.67	0.15	0.05	-0.05	-0.39	0.52	1.06	-0.11
Asset Impairment Charges	–	0	3.91	0	–	–	–	–	–	–	–	–	–
Gain (Loss) on Investments	–	–	–	–	0	5.21	0.05	0	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	–	–	0	0	-0.02	–
Pretax Income	-78	-35	-32	-42	–	–	–	–	–	–	–	–	–
Income Tax Expense	0.17	0.11	0.01	0.03	-0.20	-2.79	0.28	-0.05	1.97	0	0	–	–
Income from Continuing Operations	–	–	–	-42	-84	-64	-16	-35	–	–	–	–	–
Income from Discontinued Operations	–	–	–	0	-0.03	0.88	0.20	-4.78	–	–	–	–	–
Net Income	-78	-35	-32	-42	-84	-64	-16	-40	12	-16	-10	-16	-13
Net Income to Common	–	-35	-32	–	–	–	–	42	7.77	-16	-10	-3.52	-13
EPS (Basic)(per share)	-5.84	-7.94	-113.58	-1,063.00	–	–	–	-3,456.00	1,209.60	-5,385.60	-13,564.80	-15,782.40	-59,673.60
EPS (Diluted)(per share)	-5.84	-20.91	-113.58	-1,063.00	–	–	–	-3,456.00	1,209.60	-5,385.60	-13,564.80	-15,782.40	-59,673.60
Shares Outstanding (Basic, Weighted)(shares)	13	4.43	0.28	0.04	–	–	–	0.01	0.01	0.00	0.00	0.00	0.00
Shares Outstanding (Diluted, Weighted)(shares)	13	7.50	0.28	0.04	–	–	–	0.01	0.01	0.00	0.00	0.00	0.00
EBITDA	-73	-68	-27	-37	-80	-71	-12	-31	14	-16	-11	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -154844.1%
Net margin: -170055.9%
Return on equity, FY2025: -72.4%

Financial strength

Current ratio: 19.31
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 404.1%

Valuation

P/E ratio: –
Price to sales: 8565.22
Price to book: 1.13
Dividend yield: –